IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement IceCure (Nasdaq: ICCM) priced a registered direct offering of 8,000,000 ordinary shares at $0.50 per share for gross proceeds of approximately $4.0 million. In a concurrent private placement the company will issue Series B and Series C warrants to purchase up to 8,000,000 shares each, exercisable at $0.55.The Series B warrants expire five years after issuance; Series C warrants expire one year after issuance. Closing is expected on or about March 27, 2026. Net proceeds are intended for working capital and general corporate purposes. A.G.P./Alliance Global Partners is sole placement agent.

#ICCM IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

www.stocktitan.net/news/ICCM/ice-cure-annou...

Freezing kidney tumors left 89.4% recurrence-free in study Among 112 evaluated patients, 83.9% stayed recurrence-free at median four-year follow-up, supporting wider use of ProSense; full data arrives in April.

#ICCM IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

www.stocktitan.net/news/ICCM/ice-cure-repor...

IceCure Reports 2025 Full Year Financial & Operational Results IceCure (Nasdaq: ICCM) reported record fourth-quarter sales of $1.3M and full-year 2025 revenue of $3.379M, driven by U.S. FDA clearance for ProSense® in low-risk breast cancer, new ASBrS guideline support, and expansion plans including a 30-site ChoICE post-marketing study.Financials show gross profit $1.226M and narrowed net loss of $15.057M; cash and equivalents rose to $8.897M. Health Canada expansion application pending; patient enrollment for ChoICE expected H2 2026.

#ICCM IceCure Reports 2025 Full Year Financial & Operational Results

www.stocktitan.net/news/ICCM/ice-cure-repor...

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer IceCure (Nasdaq: ICCM) announced that the U.S. FDA approved the study design for the ChoICE Trial Post-Market Study of ProSense® cryoablation for low-risk breast cancer.Key points: FDA marketing authorization was granted in October 2025 for patients ≥70 with tumors ≤1.5 cm; enrollment is expected to start in H2 2026, targeting ~400 patients across 30 U.S. sites within 36 months, with at least 80 patients in year one. The Study will use IceCure-exclusive cryoprobes and sites may treat non-study patients commercially; procedures are eligible for CPT Category III reimbursement (about $4,000 facility fee).

#ICCM U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

www.stocktitan.net/news/ICCM/u-s-fda-approv...

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer IceCure Medical (Nasdaq: ICCM) said the American Society of Breast Surgeons' 2026 Resource Guide now recommends cryoablation as an option for selected biologically low-risk early-stage breast cancer patients. The update follows FDA marketing clearance for ProSense® in October 2025 and cites clinical evidence and multidisciplinary care principles.The guide affirms cryoablation for fibroadenomas and recognizes ProSense® as the first FDA-cleared device for low-risk breast cancer, potentially accelerating commercial adoption, aided by an established CPT III reimbursement code and an estimated U.S. addressable population of ~200,000 women annually.

#ICCM American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

www.stocktitan.net/news/ICCM/american-socie...

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas IceCure Medical (Nasdaq: ICCM) announced publication in PLOS One of an independent study showing ProSense® cryoablation is safe and effective for breast fibroadenomas.The study reported a median volume reduction of 80.6% at ~6 months and 92.9% at one year, evaluated larger lesions using up to three cryoprobe relocations, and notes ProSense® has FDA clearance for fibroadenomas.

#ICCM IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

www.stocktitan.net/news/ICCM/ice-cure-medic...

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales IceCure (Nasdaq: ICCM) reported record 2025 ProSense® sales of approximately $3.4 million and cash and cash equivalents of approximately $8.9 million as of December 31, 2025, based on preliminary unaudited estimates. In October 2025 the company received FDA marketing authorization for ProSense® for local treatment of low-risk breast cancer in women aged 70+ with endocrine therapy, making it the first and only device with that FDA authorization. The company reported record European sales, expanded scientific publications and presentations, four new U.S. and China patents, and reimbursement under CPT III at $4,049 effective January 2026.

#ICCM IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

www.stocktitan.net/news/ICCM/ice-cure-ceo-i...

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting IceCure (NASDAQ: ICCM) reported that four independent abstracts featuring its ProSense cryoablation system were presented at RSNA 2025 (Nov 30–Dec 4, 2025).Key data from three studies covering 263 patients include: 100% success for luminal cancers ≤2.5 cm, complete necrosis 81.2% in a 73‑patient cohort, Cryoablation+HT tumor reduction 83.3% (mean 13.6 mm) versus HT‑only 42.1%, and CEM showing NPV and sensitivity 100% for cryoablation assessment. The company noted growing adoption following the FDA marketing approval for low‑risk breast cancer.

#ICCM IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

www.stocktitan.net/news/ICCM/ice-cure-s-pro...

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes IceCure (NASDAQ: ICCM) received a Notice of Allowance in China for a patent titled "Cryogen Flow Control" on Dec 5, 2025, covering temperature regulation for its next-generation XSense cryoablation system and probes.The invention builds on prior intellectual property wins, with the same patent granted in Japan and pending in the EU, U.S., and other markets, and contributes to IceCure's stated 55 patents granted and allowed globally. The technology aims to use sensor-driven flow control to maintain distal tip temperatures, improve efficacy and tissue safety, and support navigation/mapping features. IceCure notes its ProSense cryoablation system has FDA marketing authorization for local treatment of low-risk breast cancer in specified patients.

#ICCM IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

www.stocktitan.net/news/ICCM/ice-cure-recei...

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 Momentum building in the U.S. and rising interest globally following landmark FDA marketing authorization for local cryoablation treatment of low-risk breast cancer. Total U.S. population of approximately 200,000 patients, includes women aged 70+, those not suitable for surgery and benign breast tumors. In October 2025, the U.S. Food and Drug...

#ICCM IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

www.stocktitan.net/news/ICCM/ice-cure-repor...

#ICCM IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

www.stocktitan.net/news/ICCM/ice-cure-s-pro...

46 days until the 10th International Congress of Chinese Mathematicians in Shanghai! There will be 1,200+ attendees, 300+ lectures, 7+ events, and several awards to outstanding mathematicians in our community! We at International Press hope to see you there! #math #mathematics #iccm #iccm2025

IceCure Medical Faces Nasdaq Minimum Bid Price Notification: Next Steps outlined IceCure Medical Ltd. has announced that it has received a Nasdaq notification regarding minimum bid price non-compliance, sparking a 180-day compliance period.

IceCure Medical Faces Nasdaq Minimum Bid Price Notification: Next Steps outlined #Israel #Caesarea #IceCure_Medical #Nasdaq_Listing #ICCM

#ICCM IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

www.stocktitan.net/news/ICCM/ice-cure-promo...

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances IceCure (Nasdaq: ICCM) announced that the U.S. Food and Drug Administration granted marketing authorization for ProSense® on October 3, 2025 for local treatment of breast cancer in patients ≥70 years with biologically low-risk tumors ≤1.5 cm treated with adjuvant endocrine therapy, and for patients not suitable for surgery.The authorization followed IceCure's participation in the TME Fall Summit (Sept 26–27, 2025), where ProSense® drew high interest from a multidisciplinary roundtable of 40+ key opinion leaders and was highlighted in de-escalation sessions and a cryoablation faculty led by Dr. Richard Fine.

#ICCM IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

www.stocktitan.net/news/ICCM/ice-cure-s-pro...

IceCure Advances Toward U.S. Approval for ProSense Cryoablation in Breast Cancer IceCure Medical (NASDAQ: ICCM) is making progress on the U.S. regulatory path for ProSense®, its liquid-nitrogen cryoablation system for early-stage, low-risk

(NASDAQ: #ICCM)
#IceCureMedical is nearing U.S. approval for ProSense cryoablation in breast cancer after a positive FDA review and plans for a key post-market study.
prismmarketview.com/icecure-adva...

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above IceCure (Nasdaq: ICCM) announced FDA marketing authorization (De Novo) on Oct 3, 2025 for its ProSense® cryoablation system to treat biologically low‑risk breast cancer in women ≥70 with tumors ≤1.5 cm, representing ~46,000 U.S. patients annually. The authorization permits immediate commercial sales and establishes a CPT III reimbursement pathway covering $3,800 of facility costs. The FDA required a post‑market surveillance study of ~400 patients at 30 sites; those sites may also serve commercial patients. FDA set a 5‑year follow‑up data expectation for competitors seeking 510(k) clearance. A company webcast is scheduled for Oct 6, 2025 at 8:30 AM ET.

#ICCM IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

www.stocktitan.net/news/ICCM/ice-cure-recei...

Trade Alerts, Thursday September 11, 2025 – Crystal Equity Research

Small-cap stocks registering bearish MACD crossover signal, Thu Sept 11th - #ENTO #VSTM #TCRX #SRCE #RBBN #PINC #OSBC #MGNX #LOVE #ICCM #HSON #FISI $ELVA $DAWN $COGT $CCRN $BCAX $ACIC $TEN $SCM $PINE $ONL $NMM $MFA - More: crystalequityresearch.com/trade-alerts... - #smallcap

Pain Scores Drop from 8/10 to Zero: IceCure's ProSense Shows Breakthrough Results in Endometriosis Treatment Clinical study shows IceCure's ProSense cryoablation eliminated endometriosis pain in all patients, with 15-min procedure time. No complications reported in 14-patient trial at Nîmes Hospital.

#ICCM IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

www.stocktitan.net/news/ICCM/ice-cure-s-pro...

#ICCM #ff54542d-9418-4936-aaa7-fd71f787cf99 #earningscall-transcripts

Origin | Interest | Match

IceCure's Breast Cancer Treatment Device Approaches FDA Decision as Investors Double Down with $10M Backing ProSense cryoablation system targets 46,000 early-stage breast cancer patients annually. FDA marketing approval expected by year-end following successful funding round. Learn more.

#ICCM IceCure Reports Financial & Operational Results for the First Half of 2025

www.stocktitan.net/news/ICCM/ice-cure-repor...

IceCure Medical Rights Offering Draws Massive Investor Interest: $10M Raise Sees 2X Demand Strong investor demand leads to 2X oversubscription in IceCure's latest financing round. See full details of the $10M rights offering and upcoming warrant distribution.

#ICCM IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

www.stocktitan.net/news/ICCM/ice-cure-annou...

Revolutionary Breast Cancer Treatment Achieves 99% Success Rate: 600+ Patient Study Reveals Groundbreaking Results New clinical data reveals breakthrough 99% success rate for minimally-invasive breast cancer treatment across 600+ patients. Award-winning study confirms long-term efficacy. See results.

#ICCM IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

www.stocktitan.net/news/ICCM/ice-cure-s-pro...

IceCure Announces Commencement of Rights Offering IceCure Medical (Nasdaq: ICCM), a developer of cryoablation technology, has launched a rights offering to raise up to $10 million through the distribution of subscription rights to existing shareholders. Each shareholder will receive one subscription right per ordinary share held as of July 9, 2025, allowing them to purchase 0.1703 units at $1.00 per unit.Each unit consists of one ordinary share and a warrant to purchase one ordinary share. Epoch Partner Investments, IceCure's largest shareholder, has committed to invest up to $5 million in the offering. The subscription period runs from July 10 to July 28, 2025. Proceeds will be used to repay a $2 million bridge loan from Epoch and for general corporate purposes.

#ICCM IceCure Announces Commencement of Rights Offering

www.stocktitan.net/news/ICCM/ice-cure-annou...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Tue Jul 8th - #HIFS #GAME #FTFT #CVAC #BWMN #API #CARS #BUR #ARMN #ICCM #LGVN #NBBK #OBLG #PROK #RWAY #SNWV #TLRY #WKHS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025 IceCure Medical (NASDAQ: ICCM), a developer of cryoablation technology for tumor treatment, released preliminary financial results for Q2 and H1 2025. The company expects Q2 2025 product sales of $525,000, with over $200,000 in delayed shipments moving to Q3 2025 due to temporary logistics issues related to the Israel-Iran conflict.For H1 2025, product sales reached approximately $1.25 million, down from $1.65 million in H1 2024. The company maintains that order flow remained stable despite regional conflicts, with delays primarily affecting non-U.S. markets. U.S. operations continued normally due to sufficient ProSense® inventory. Complete Q2 and H1 2025 financial results will be released in August 2025.

#ICCM IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

www.stocktitan.net/news/ICCM/ice-cure-repor...

IceCure Announces Record Date for Rights Offering for Up to $10 Million IceCure Medical (NASDAQ: ICCM), a developer of cryoablation technology for tumor treatment, has announced a rights offering to raise up to $10 million. Shareholders of record as of July 9, 2025, will receive one subscription right for each ordinary share, allowing them to subscribe for 0.1703 units at $1.00 per unit.Each unit consists of one ordinary share and a warrant to purchase one ordinary share. Epoch Partner Investments, IceCure's largest shareholder, has committed to participate with up to $5 million. The proceeds will be used to repay a $2 million bridge loan from Epoch and for general corporate purposes. The subscription period runs from July 10 to July 28, 2025.

#ICCM IceCure Announces Record Date for Rights Offering for Up to $10 Million

www.stocktitan.net/news/ICCM/ice-cure-annou...

IceCure's New Cryoablation Patent Could Transform Breast Cancer Treatment - FDA Decision Pending Novel cryogen flow control patent strengthens IceCure's tumor treatment platform through 2045. Awaiting FDA decision on breast cancer therapy. Learn more.

#ICCM IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

www.stocktitan.net/news/ICCM/ice-cure-recei...

www.fool.com/earnings/call-transcript...

#ICCM #266d7478-b204-4b61-9c18-401b2d5b7ac9 #earningscall-transcripts

Result Details